Mersana Therapeutics, Inc.
MRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.05 | 0.28 | -0.04 |
| FCF Yield | -47.06% | -63.50% | -9.39% | -32.03% |
| EV / EBITDA | -1.52 | -0.77 | -2.28 | -1.78 |
| Quality | ||||
| ROIC | -74.41% | -101.82% | -82.97% | -104.95% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.19 | 0.98 | 0.24 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.07% | 849.90% | 217.82% | 350,239.81% |
| Free Cash Flow Growth | 51.78% | -231.75% | 63.34% | -87.09% |
| Safety | ||||
| Net Debt / EBITDA | 1.25 | 0.85 | 0.46 | 0.83 |
| Interest Coverage | -18.93 | -41.97 | -61.23 | -133.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 411.95 | 0.00 |